Exclusive License Fee Sample Clauses

Exclusive License Fee. Within *** days of exercising the Option to an exclusive license as provided in Section 2.2 above, Licensee shall pay University an additional one-time, non-creditable, non-refundable license fee of *** dollars ($***).
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
Exclusive License Fee. If LICENSEE decides to exercise its Exclusive Option to acquire an exclusive license to an Optioned Patent, then LICENSEE shall pay STANFORD an exclusive license fee of [*] Dollars ($[*]) within [*] of exercising such Exclusive Option (“Exclusive License Fee”). The amount of the Exclusive License Fee shall be agreed to by STANFORD and LICENSEE taking into account the Fee Criteria, as set forth below. If STANFORD and LICENSEE do not agree on the amount, a mutually agreeable third party will determine the amount based on the Fee Criteria and industry standards. In any case, the amount may not be less than [*] Dollars ($[*]) and not more than [*] Dollars ($[*]). STANFORD agrees that the amount of the Exclusive License Fee will be determined taking into account such factors as whether: (i) third party technology licensed to LICENSEE is used in conjunction with the invention claimed in the patent; (ii) the claims of the patent are method claims or are composition of matter claims that do not encompass the product to be sold or its method of manufacture; and, (iii) LICENSEE’S financial position is that of an early stage biotechnology company (meaning that the company has not commercialized a therapeutic or diagnostic product and has less than [*] dollars in liquid assets) (“Fee Criteria”). The Exclusive License Fee is due only once for each New Exclusive Patent. LICENSEE may convert a New Exclusive Patent to a New Non-Exclusive Patent upon written notice to STANFORD at any time.
Sample 1Sample 2
Exclusive License Fee. If Licensee decides to exercise its option to acquire an Exclusive license to an Optioned Patent, then Licensee shall pay Stanford an Exclusive license fee of [**]dollars ($[**]) within [**] of the issuance of the first patent claiming priority to such New Licensed Patent. The amount of the Exclusive license fee shall be determined by Stanford. Stanford agrees that reductions in the Exclusive license fee (to not less than [**] dollars ($[**])) may be appropriate when (i) third party technology licensed to Licensee is used in conjunction with the invention claimed in the patent; or (ii) the claims of the patent are method claims or are composition of matter claims that do not encompass the product to be sold or its method of manufacture. The Exclusive license fee is due only once for each New Licensed Patent. Licensee may convert a New Licensed Patent to a New Non-Exclusive Patent upon written notice to Stanford at any time. E.
Sample 1Sample 2
Exclusive License Fee. This Distribution, Use, Sale and Lease Exclusive License fee is $75,000,000 USD (Seventy Five Million US Dollars). Based on the size of this project and order presented to the Company and the vast potential expansion of hydrogen applications, Company management has agree to forgive the exclusive license fee of $75,000,000 USD and work with Secure Supplies HK LLC to move this project forward in an expedited fashion.
Sample 1

Related to Exclusive License Fee

  • Exclusive License Licensor hereby grants to Licensee and Licensee hereby accepts from Licensor, upon the terms and conditions herein specified, a sole and exclusive license under the Licensed Patent Rights in the Territory, and in the Field of Use to develop, make, have made, import, have imported, use, offer to sell, sell and otherwise commercialize Licensed Product(s).

  • Exclusive License Grant Subject to the terms and conditions of this Agreement, Licensee hereby grants to Takeda an exclusive, sublicensable (subject to Section 3.3 (Sublicensing)), royalty-bearing right and license under the Licensee Technology and Licensee’s interest in the Joint Technology to Exploit the TAK-385 Licensed Compound and TAK-385 Licensed Products in the Field in the Takeda Territory.

  • Non-Exclusive License Grant Subject to the terms and conditions of this Agreement, Takeda hereby grants to Licensee a non-exclusive, sublicensable (subject to Section 3.3 (Sublicensing)) right and license under the Takeda Technology and Takeda’s interest in the Joint Technology to: (a) Develop the TAK-385 Licensed Compound and TAK-385 Licensed Products in the Men’s Health Field in the Takeda Territory solely for the purpose of Exploiting such Licensed Products in the Field in the Licensee Territory, or as required in order for Licensee to comply with its diligence obligations set forth in Section 5.2 (Development Diligence Obligations) and (b) Manufacture the TAK-385 Licensed Compound and TAK-385 Licensed Products in the Takeda Territory.

  • License Fee Controlled Affiliate will pay to BCBSA a fee for this License determined pursuant to the formula(s) set forth in Exhibit B.

  • Non-Exclusive License NCPS grants Company a revocable, non-exclusive, non-transferable and non-sublicensable license during the Term to view-only access the PPEX ATS through the PPEX Site and its related software and other applications and technology for the sole purpose of viewing information about Company and Company Securities and Trades of Company Securities. This license is in addition to the license Company has and is required to maintain during the Term (as defined below) with NCPS’s affiliate, North Capital Investment Technology, Inc., for TransactAPI pursuant to a separate Software and Services License Agreement (“SSLA”). The technology covered by the licenses outlined in this Section 2 is collectively referred to herein as the “Technology”.

  • Sublicense Fees Licensee will pay Sublicense Fees indicated in Section 3.1(e) of the Patent & Technology License Agreement on or before the Quarterly Payment Deadline for the Contract Quarter.

  • License Fees If so provided in the Prospectus, the Depositor may enter into a Licensing Agreement (the "Agreement") with a licensor (the "Licensor") described in the Prospectus in which the Trust(s), as consideration for the licenses granted by the Licensor for the right to use its trademarks and trade names, intellectual property rights or for the use of databases and research owned by the Licensor, will pay a fee set forth in the Agreement to the applicable Licensor or the Depositor to reimburse the Depositor for payment of the expenses. If the Agreement provides for an annual license fee computed in whole or part by reference to the average daily net asset value of the Trust assets, for purpose of calculating the accrual of estimated expenses such annual fee shall accrue at a daily rate and the Trustee is authorized to compute an estimated license fee payment (i) until the Depositor has informed the Trustee that there will be no further deposits of additional Securities, by reference to an estimate of the average daily net asset value of the Trust assets which the Depositor shall provide the Trustee, (ii) thereafter and during the calendar quarter in which the last business day of the period described in clause (i) occurs, by reference to the net asset value of the Trust assets as of such last business day, and (iii) during each subsequent calendar quarter, by reference to the net asset value of the Trust assets as of the last business day of the preceding calendar quarter. The Trustee shall adjust the net asset value (Trust Fund Evaluation) as of the dates specified in the preceding sentence to account for any variation between accrual of estimated license fee and the license fee payable pursuant to the Agreement, but such adjustment shall not affect calculations made prior thereto and no adjustment shall be made in respect thereof.

  • License Maintenance Fee Beginning on the first anniversary of the Effective Date, and on each anniversary of the Effective Date thereafter during the term of the Agreement, Company shall pay to Medical School {***}. This annual license maintenance fee is nonrefundable and is not creditable against any other payments due to Medical School under this Agreement.

  • License Maintenance Fees Licensee will pay license fees in the amounts set forth in Sections 3.1(d) of the Patent & Technology License Agreement in accordance with the stated schedule.

  • Know-How Royalty Notwithstanding the provisions of Section 5.4.1(a), in countries where the sale of Product by Merck or its Related Parties would not infringe a Valid Patent Claim, Merck shall pay royalty rates that shall be set at [***] of the applicable royalty rate determined according to Section 5.4.1(a). Such royalties shall be calculated after first calculating royalties under Section 5.4.1(a).

Time is Money Join Law Insider Premium to draft better contracts faster.